These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. J Gastroenterol Hepatol; 2009 Mar; 24(3):399-407. PubMed ID: 19067776 [Abstract] [Full Text] [Related]
25. Pharmacologic management of isolated low high-density lipoprotein syndrome. Bermúdez V, Cano R, Cano C, Bermúdez F, Arraiz N, Acosta L, Finol F, Pabón MR, Amell A, Reyna N, Hidalgo J, Kendall P, Manuel V, Hernández R. Am J Ther; 2008 Mar; 15(4):377-88. PubMed ID: 18645343 [Abstract] [Full Text] [Related]
26. Reducing the risks of cardiovascular disease in liver allograft recipients. Mells G, Neuberger J. Transplantation; 2007 May 15; 83(9):1141-50. PubMed ID: 17496526 [Abstract] [Full Text] [Related]
27. Obesity: a main factor of metabolic syndrome? Licata G, Argano C, Di Chiara T, Parrinello G, Scaglione R. Panminerva Med; 2006 Jun 15; 48(2):77-85. PubMed ID: 16953145 [Abstract] [Full Text] [Related]
28. PPARs as targets for the modulation of cardiovascular risk factors associated with the metabolic syndrome. Fernandez AZ. Curr Opin Investig Drugs; 2004 Sep 15; 5(9):936-40. PubMed ID: 15503647 [Abstract] [Full Text] [Related]
30. The metabolic syndrome in women. Schneider JG, Tompkins C, Blumenthal RS, Mora S. Cardiol Rev; 2006 Sep 15; 14(6):286-91. PubMed ID: 17053375 [Abstract] [Full Text] [Related]
31. Cardiovascular risk factors in the metabolic syndrome: impact of insulin resistance on lipids, hypertension, and the development of diabetes and cardiac events. Zarich SW. Rev Cardiovasc Med; 2005 Sep 15; 6(4):194-205. PubMed ID: 16379015 [Abstract] [Full Text] [Related]
32. Metabolic syndrome: nature, therapeutic solutions and options. Onat A. Expert Opin Pharmacother; 2011 Aug 15; 12(12):1887-1900. PubMed ID: 21756201 [Abstract] [Full Text] [Related]
33. Doxazosin in metabolically complicated hypertension. Dell'Omo G, Penno G, Del Prato S, Pedrinelli R. Expert Rev Cardiovasc Ther; 2007 Nov 15; 5(6):1027-35. PubMed ID: 18035918 [Abstract] [Full Text] [Related]
37. Metabolism, lifestyle and bipolar affective disorder. Morriss R, Mohammed FA. J Psychopharmacol; 2005 Nov 15; 19(6 Suppl):94-101. PubMed ID: 16280342 [Abstract] [Full Text] [Related]
38. Lowering the threshold for defining microalbuminuria: effects of a lifestyle-metformin intervention in obese "normoalbuminuric" non-diabetic subjects. Cubeddu LX, Alfieri AB, Hoffmann IS. Am J Hypertens; 2008 Jan 15; 21(1):105-10. PubMed ID: 18091752 [Abstract] [Full Text] [Related]